Claudin18.2分子特征概述及其作为治疗靶点在胃癌中的研究进展  

Overview of the molecular characterization of Claudin18.2 and its progress as a therapeutic target in gastric cancer

作　　者：王桂慧 廖海燕 何媚 靳枫[2] 王树滨[2] 高静 Wang Guihui;Liao Haiyan;He Mei;Jin Feng;Wang Shubin;Gao Jing(Medical College,Shantou University,Shantou 515041,Guangdong,China;Department of Oncology,Peking University Shenzhen Hospital,Shenzhen 518036,Guangdong,China)

机构地区：[1]汕头大学医学院,广东汕头515041 [2]北京大学深圳医院肿瘤科,广东深圳518036

出　　处：《肿瘤综合治疗电子杂志》2024年第2期146-154,共9页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：深圳市政府三名工程项目(SZSM202211036)。

摘　　要：作为紧密连接蛋白(Claudin,CLDN)家族成员之一,Claudin18.2(CLDN18.2)在正常情况下仅在正常胃黏膜上皮细胞中表达,以维持细胞正常功能。但在异常情况下,CLDN18.2在包括胃癌在内的多种恶性肿瘤中呈高表达状态,使其成为治疗前景非常高的新靶点。目前,靶向CLDN18.2的抗肿瘤新药研发如火如荼,药物类型和治疗策略呈现多样化。本文旨在概述CLDN18.2的分子特征,并对胃癌中靶向CLDN18.2的新药/新技术研发现状进行梳理,包括单克隆抗体、双特异性抗体、抗体药物偶联物、嵌合抗原受体T细胞免疫疗法、纳米抗体等。As a member of the tight junction protein(Claudin,CLDN)family,Claudin18.2(CLDN18.2)is typically expressed exclusively in normal gastric mucosal epithelial cells to maintain normal cellular functions.However,CLDN18.2 is highly expressed in various malignant tumors including gastric cancer under abnormal conditions,making it a promising therapeutic target.Currently,studies focused on research and development of new antitumor drugs targeting CLDN18.2 are very popular,employing diverse drug types and therapeutic strategies.This review aims to provide a concise overview of the molecular characterization of CLDN18.2 and summarize the current research and development status of new drugs/technologies targeting CLDN18.2 in gastric cancer.These include monoclonal antibodies,bispecific antibodies,antibody-drug conjugate,chimeric antigen receptor T-cell immunotherapy,nanobodies and so on.

关 键 词：胃癌 紧密连接蛋白 Claudin18.2(CLDN18.2) 分子特征 治疗靶点 

分 类 号：R735.2[医药卫生—肿瘤]